Introduction {#sec1-1}
============

Gliosarcoma is a rare but distinct clinicopathological entity in the classification of central nervous system tumors and constitutes approximately 2% of all the malignant glial neoplasms.\[[@ref1]\] It is considered as a grade IV neoplasm and classified as a variant of glioblastoma multiforme (GBM) in the revised 2007 WHO classification.\[[@ref2]\] Gliosarcoma was first reported by Heinrich Strobe in 1895 as a brain tumor consisting of both glial and mesenchymal components.\[[@ref3]\] Malignant astrocytes constitute the majority of the glial component in gliosarcomas; however, oligodendroglial components have also been described. Typically sarcomatous components resemble fibrosarcoma or malignant fibrous histiocytoma. The purpose of this study is to evaluate retrospectively the clinicopathological features and treatment outcomes in patients of primary gliosarcoma.

Materials and Methods {#sec1-2}
=====================

Medical records of patients registered over a 5-year period (2009-2013) in the Regional Cancer Centre, PGIMER, Chandigarh, were retrospectively analyzed, and data was collected on primary gliosarcomas. Treatment outcomes were analyzed using SPSS version 18.

Results {#sec1-3}
=======

Patient characteristics {#sec2-1}
-----------------------

Twenty-seven patients were included in this study, the characteristics of whom are presented. Median age at diagnosis was 54 years (range, 9-69 years), with a male predominance (male to female ratio, 1.25:1). Most patients presented with signs and symptoms of raised intracranial pressure, the median duration of symptoms being 2 months (range, 2-6 months), with a Karnofsky performance status (KPS) of 70. Localizing symptoms were also a common presenting feature, ranging from motor deficits (48.1%), cognitive impairment (22%), seizures (18.5%), to visual impairment (11.1%).

Radiological picture {#sec2-2}
--------------------

On Computed tomography (CT) scan, they are often seen as supratentorial, sharply defined, lobulated or round hyperdense solid masses, with a relatively homogeneous contrast enhancement, along with peritumoral edema. On magnetic resonance imaging (MRI), they are characteristically seen as well-demarcated peripheral lesions abutting a dural surface, with uneven and thick-walls having ring-like enhancement and intratumoral strip enhancement \[[Figure 1](#F1){ref-type="fig"}\]. In this retrospective analysis, all tumors were supratentorial in location with temporal lobe being the most common (48.1%). Frontal and parietal involvement was seen in 11 and eight patients, respectively. Occipital location was found in two cases. Tumors were multilobed in 11 patients and multicentric in three patients.

![T1 weighted contrast enhanced MRI showing heterogenously enhancing lesion in Right fronto temporal region with significant perilesional edema and mass effect](SAJC-4-15-g001){#F1}

Surgery {#sec2-3}
-------

All patients underwent maximally possible safe surgery. Gross total resection was done in 16 (59.3%) cases, near total resection in five cases, while only subtotal resection for decompression was possible in six cases.

Histopathology {#sec2-4}
--------------

All tumors in this study fulfilled the criteria for gliosarcoma showing biphasic histologic pattern consisting of a gliomatous and sarcomatous components as shown in [Figure 2](#F2){ref-type="fig"}. Glial component was strongly positive for glial fibrillary acidic protein (GFAP), with vascular proliferation, nuclear atypia, and areas of necrosis; the sarcomatous component was positive for vimentin and reticulin but further characterization was not done. Molecular profiling could not be done in most of our patients because of financial constraints in a developing country like ours.

![Photomicrograph of gliosarcoma showing fascicles of sarcomatous area alternating with gliomatous areas](SAJC-4-15-g002){#F2}

Adjuvant treatment {#sec2-5}
------------------

Postoperative radiotherapy (PORT) was delivered in 26 cases, with one drop-out after registration. The median interval between surgery and PORT was 6 weeks. Twenty-one patients received external beam radiotherapy of 60 Gy in 30 fractions over a 6-week period. Four patients received hypofractionated radiotherapy of 40 Gy in 15 fractions in three weeks due to poor performance status. All patients were treated with conformal radiotherapy. One patient defaulted due to poor tolerance. Radiation is delivered in two phases---phase I (base): 40 Gy/20\#/4 weeks to contrast enhancing tumor (on T1-weighted MRI) with a margin of 3 cm; phase II (boost): 20 Gy/10\#/2 weeks to contrast enhancing tumor with a margin of 1 cm. Temozolomide was given concurrently at 75 mg/m^2^ throughout the course of radiation including weekends, followed by adjuvant temozolomide at 150-200 mg/m^2^ from day 1 to day 5 at 4 weekly intervals for six cycles in 11 patients who could afford and tolerate the drug.

Response to treatment {#sec2-6}
---------------------

Ten patients were asymptomatic at completion of treatment. Six patients improved clinically, and six patients deteriorated during or at completion of radiotherapy. Neurological status improved in 20% of patients. Salvage surgery was not done in any of our patients for recurrence. One of the patients received bevacizumab 10 mg/kg 2 weekly for six cycles. Another patient received lomustine 80 mg 6 weekly for three cycles.

Survival analysis {#sec2-7}
-----------------

All 27 patients were eligible for demographic analysis. However, for adjuvant treatment, the drop outs were excluded, and 26 patients were analyzed. The median follow up period was 6.2 months. Median overall survival was 9 months (range, 2-22 months). Six month overall survival was 70%. On subgroup analysis, median overall survival in the radiotherapy plus temozolomide group was 10 months as compared to 9 months in the radiotherapy alone group; however, this was not statistically significant (*P* = 0.244). \[[Figure 3](#F3){ref-type="fig"}\].

![Kaplan Meier curve showing impact of addition of Temozolomide to Radiotherapy alone on survival](SAJC-4-15-g003){#F3}

Discussion {#sec1-4}
==========

Gliosarcoma is a rare intracranial neoplasm and comprises 1.8-2.8% of all GBMs.\[[@ref1]\] In our center, gliosarcomas constitute 3.61% (27/748) of all GBM in the last 5 years.

The histogenesis of the sarcomatous portion of gliosarcoma has been a matter of controversy since its initial description. Early reports suggested that the sarcomatous components originated from the neoplastic transformation of hyperplastic blood vessels commonly found in high-grade gliomas. Recent genetic studies revealed the presence of identical p53 and phosphatase and tensin homolog (PTEN) mutations and similar chromosomal imbalances and cytogenetic alterations in both components of gliosarcomas suggesting a monoclonal origin.\[[@ref4][@ref5]\] The predominance of sarcomatosis is associated with a better prognosis and a longer period of time without recurrence.\[[@ref6]\]

Gliosarcomas typically affect adults in their fourth to sixth decade, with significant male preponderance (male: female = 1.8:1).\[[@ref7]\] Median age of presentation of our patients is 54 years, which is identical to other series.

The striking features of gliosarcoma that distinguish it from GBM include its location and its differential radiographic and gross appearance. Gliosarcomas are usually supratentorial in location with temporal lobe being the most common site involved.\[[@ref7][@ref8]\] This retrospective analysis also showed temporal lobe predilection followed by frontal and parietal lobe involvement.

Though extracranial metastasis from GBM is rare, gliosarcomas are well-known for their systemic dissemination. Most common sites of extracranial metastasis are the lungs and the liver.\[[@ref9]\] Smith *et al*.,\[[@ref10]\] in their largest series of seven cases of metastatic gliosarcoma noted that in two cases the metastatic foci were composed solely sarcomatous components. Metastatic potential of gliosarcoma is due to its sarcomatous component that has a strong propensity for hematogenous spread.

The majority of information on primary gliosarcoma therapy is derived from published case series. Typically, the described therapeutic approach is based on the prevailing treatment recommendations for GBM, including maximal safe surgical resection followed by adjuvant radiation therapy and temozolomide-based chemotherapy.\[[@ref11]\] The total dose delivered in radiotherapy ranged from 45 to 81 Gy in different reports.\[[@ref1][@ref7]\] The benefit of radiation therapy on survival of patients was described by Perry *et al*., as radiation-treated patients had median survival of 10.6 months compared to 6.25 months in patients not treated with radiation (*P* = 0.025).\[[@ref12]\] At our center, 80.76% patients received the standard dose external beam radiotherapy of 60 Gy in 30 fractions after maximal safe surgery. Conformal radiotherapy was used in all of our patients, unlike our previously published study where only 46.7% received 3d-CRT.\[[@ref13]\]

Although chemotherapy with temozolomide is now the standard of care for GBM, the precise role of chemotherapy remains uncertain for primary gliosarcoma. Morantz *et al*., observed a modest increase in survival for these patients when chemotherapy with mithramycin and ametophterin (dose not reported) was added to postsurgical radiation alone (36, 33 weeks respectively, no *P* value given).\[[@ref14]\] Other authors did not offer chemotherapy to study participants, citing its ill-defined role. Though the role of chemotherapy in the management of gliosarcoma is not well defined, we have used concurrent and adjuvant temozolomide following the lines of management of GBM; 42.3% patients received concurrent and adjuvant temozolomide, which was much higher from our previous series where only two patients received temozolomide. With addition of temozolomide in a fair number of patients, median overall survival improved by one month in the chemoradiation arm. Though it was not statistically significant, it has definitely shown a trend towards benefit.

The prognosis for gliosarcoma is generally poor, with an average survival ranging from 8-24 months from the onset of symptoms.\[[@ref14]\] Meis *et al*.,\[[@ref15]\] reported median survival of 8.3 months for gliosarcoma patients as compared to 9.6 months for GBM patients. Multiple other case series\[[@ref16][@ref17]\] have shown similar results with poorer outcomes for primary gliosarcomas as compared to GBMs. In our series, median overall survival is approximately 9 months, which is considerably comparable with other studies. We could improve the outcomes from our previous series\[[@ref13]\] possibly because of improved dose delivery by conformal techniques and increased use of temozolomide as radiosensitizer. Though addition of temozolomide has not significantly improved survival, it has shown a definite trend towards benefit compared to radiation alone. However, there is room for further improvement if we could decrease the median gap between surgery and radiotherapy because of delayed referrals and long waiting lists from 6 weeks in our series to the recommended 2-4 weeks.

There is very little data regarding the response of gliosarcomas to novel therapies. In future, attention needs to be focused on the cellular and molecular biology of gliosarcoma pertaining to tumor proliferation, invasion, angiogenesis, interaction with extracellular matrix and promoter methylation status of the DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT), and amplification of EGFR. Studies have shown a strong association between MGMT promotor-methylated tumors and PTEN positivity with improved survival.\[[@ref18]\]

Conclusion {#sec1-5}
==========

Gliosarcoma is a rare clinicopathological entity. The optimum treatment of gliosarcoma is not yet well defined; however, they are treated along the lines of GBM as of now. Increased use of conformal radiation and concurrent temozolomide helped us improve the median overall survival and 6-month survival to 9 months and 70% as compared to 8.27 months and 60.7%, respectively, from our previously published series. In future, attention needs to be focused on the cellular and molecular biology of gliosarcoma, which will help us to modify the treatment and may improve further survival.
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